GoldenGolden
Advanced Search
Roivant Sciences

Roivant Sciences

Roivant Sciences is a pharmaceutical company founded by Vivek Ramaswarmy. It focuses on the discovery and development of late-stage drug candidates.

Roivant was founded in 2014 by former hedgefund analyst Vivek Ramaswarmy on the basis that the company will attempt to buy late stage pipeline molecules that are abandoned or shelved by other pharma companies.

Funding

The company has raised in excess of $2.7bn, $1bn of which originates from the Softbank New Vision fund. The company is headquartered in Basel, Switzerland but is run under a Bermuda holding entity for tax efficiency, similar to how an investment fund is structured.

Company strategy

Roivant's first acquisition was an Alzheimers drug originally developed by GlaxoSmithKline sold to Axovant (subcompany owned by Roivant) for $20m. The drug, Interpirdine, an H5-ST2A receptor agonist is in Phase 2B, despite early set backs when it failed to meet its clinical end points in the original phase 2 trial. Gsk licensed the drug to Roivant based on, what is likely a risk adjusted NPV and a review of against other pipeline drugs in which a gated investment strategy makes necessary a trade off in investment dollars for drugs that have the highest estimated peak sales and corresponding r-NPV. GSK, for instance, may want to focus the estimated $1bn it takes to bring the molecule to market on other molecules in its pipeline and hence wanted to offload Interpirdine and recoup as much of its original investment into pre-clinical and other R&D. Roivant is betting that the probability of passing the acquired molecules as higher than the originator pharmaceutical and that additional FDA approvals for indications can be attained.

Company structure

Roivant is a holding company for a number of subcompanies called 'Vants' controlled by Roivant but operated almost as individual and autonomous companies. In a competitor such as Novartis or GlaxoSmithKline, the drugs would be operated within a brand franchise rather than autonomous entities.

Timeline

Funding rounds

People

Name
Role
LinkedIn

Vivek Ramaswarmy

Founder

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Kyle LaHucik
September 24, 2021
FierceBiotech
After about a year at Roivant Sciences, Roger Sidhu, M.D., is headed for the exit to take up the chief medical officer post at a smaller biotech, Brooklyn ImmunoTherapeutics.
Annalee Armstrong
August 2, 2021
FierceBiotech
Roivant Sciences was ready to go all-in on bringing former subsidiary Immunovant back under its wing, but now, the parent-to-be is taking a step back and offering up a $200 million strategic investment instead. The complex deal came to light back in May, when Roivant said it planned to reacquire Immunovant, which left the nest and went public via a $100 million special purpose acquisition company, or SPAC, deal in 2019.
Roivant Sciences
June 9, 2021
www.prnewswire.com:443
/PRNewswire/ -- Roivant Sciences today announced that Datavant, the leader in helping healthcare organizations securely connect their data, and Ciox Health,...
Kyle LaHucik
June 1, 2021
FierceBiotech
Call it a double whammy for Immunovant. The clinical-stage biotech hit another roadblock with its lead drug candidate, IMVT-1401, just as Chief Medical Officer Rita Jain makes an abrupt exit after five months with the company.
Monteverde & Associates PC
May 22, 2021
www.prnewswire.com:443
/PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS...
Amirah Al Idrus
May 20, 2021
FierceBiotech
Roivant Sciences inked a SPAC deal to go public earlier this month, but it's not getting off the SPAC track just yet. The company wants to reacquire Immunovant, one of its subsidiaries, which went public in late 2019 through a different SPAC.
Amirah Al Idrus
May 3, 2021
FierceBiotech
As Roivant Sciences gears up its "next chapter," the company is heading for the public markets by merging with a special purpose acquisition company, or SPAC, and raising $611 million in the process.
May 3, 2021
BioSpace
Roivant Sciences and Montes Archimedes Acquisition Corp. (MAAC) to Combine and Create Publicly Traded Leader in Biopharma and Health Technology - read this article along with other careers information, tips and advice on BioSpace
Conor Hale
February 26, 2021
FierceBiotech
Roivant Sciences has moved to take molecule designer Silicon Therapeutics underneath its corporate umbrella in a deal worth $450 million or more that will merge its computational physics work into its VantAI drug discovery outfit.
Roivant Sciences
February 26, 2021
www.prnewswire.com:443
/PRNewswire/ -- Roivant Sciences today announced it has entered into a definitive agreement to acquire Silicon Therapeutics for $450 million in Roivant equity,...
Roivant Sciences
January 8, 2021
www.prnewswire.com:443
/PRNewswire/ -- Roivant Sciences today announced that Vivek Ramaswamy, Founder and Chief Executive Officer of Roivant, will present an overview of recent...
Nick Paul
December 7, 2020
FierceBiotech
Roivant Sciences has secured $200 million to advance its protein degradation ambitions. Armed with the money, Roivant CEO Vivek Ramaswamy plans to use the VantAI platform to spawn multiple new biotech startups.
Roivant Sciences
December 7, 2020
www.prnewswire.com:443
/PRNewswire/ -- Roivant Sciences today unveiled its targeted protein degradation platform which includes novel degraders for multiple diseases across oncology,...
BioSpace
November 12, 2020
BioSpace
Roivant Sciences today named EVERSANATM, the pioneer of next-generation commercial services to the global life sciences industry, a preferred provider of commercial services worldwide
Kate Goodwin
November 10, 2020
BioSpace
Affimed receives $60 million up front with potential for up to $2 billion more in partnership deal with Roivant Sciences.
Ken Banta
May 15, 2020
Harvard Business Review
Three ways to improve your R&D efforts.
Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.